i-Base home
Search Menu
  • Home
  • HTB
  • 2000
  • April

HTB

April 2000

Contents

Editorial

  • Welcome to HIV Treatment Bulletin (incorporating DrFax)

Treatment alerts

  • St John’s Wort: message from Professor A Breckenridge, Chair, Committee on Safety of Medicines.

Conference reports

  • 7th Conference on Retroviruses and Opportunistic Infections (ROI), January 30-February 2 2000, San Francisco
  • Paediatrics: children are not small (or miniature) adults
  • HIV-positive women, pregnancy and newborns
  • Flu-like symptoms of severe acute HIV infection develop after suspension of HAART
  • Non-clade B virus: epidemiology, testing strategies and resistance

Treatment strategies

  • French National Drug Agency re-commends use of IL-2 if HAART does not lead to an increase in CD4 count to greater than 200 cells/mm3

PK and drug interactions

  • Interactions of St John’s Wort (Hypericum perforatum) preparations
  • Important safety information for people taking St John’s Wort preparations

Guidelines

  • Public Health Service (US) releases updated guidelines for treatment of HIV positive pregnant women

Other news

  • French National Drug Agency re-commends use of IL-2 if HAART does not lead to an increase in CD4 count to greater than 200 cells/mm3
  • Public Health Service (US) releases updated guidelines for treatment of HIV positive pregnant women (April 2000)
  • French Health Authority approves enteric coated ddI
  • U.S. FDA approves film-coated nelfinavir mesylate (Viraceptâ„¢)
  • St John’s Wort

PDFs

  • Volume 1 Number 1 April 2000 PDF
  • HTB RSS

Early access

  • No benefit from BRII and GSK monoclonal antibodies in ACTIV-3 study 5 March 2021
  • Chronic kidney disease (CKD) in HIV positive people linked to time with low CD4 count: partly reversible after effective ART 1 March 2021
  • All early access reports

Current issues

  • March 2021
  • February 2021
  • January 2021
  • Back issues

Special report

  • Early results report 90% efficacy with from Pfizer/BioNTech COVID vaccine 11 November 2020

More from HTB

  • Conference reports
  • Conference shortcuts
  • Articles by subject
  • PDFs
  • Subscribe
  • HTB homepage

Home

  • i-Base homepage

This website sets no cookies from us or anyone else.

Information on this website is provided by treatment advocates and offered as a guide only. Decisions about your treatment should always be taken in consultation with your doctor.

This site complies with the HONcode standard for trustworthy health information.

Verify here.

HIV i-BASE
About us - Contact - Cookies and privacy - Copyright waiver - Terms of use - Home
107 The Maltings, 169 Tower Bridge Road, London SE1 3LJ.
Tel + 44 (0) 208 616 2210. Email admin@i-base.org.uk
Registered charity no: 1081905. Company reg no: 3962064.

Search i-Base

Site navigation

Quick links
HIV positive
Advocate
Professional
Donate
Feedback
Advice and information
Q and A
Phoneline
Pocket info
Guides
HIV meds
Glossary
Research and conference reports
HTB
HTB South
Pipeline report
Publications and resources
Publications
Other resources
Translations
Slide sets
Order and subscribe
News and updates
News
Blogs
Advocates' network
UK-CAB
Training manual
i-Base
About us
Contact
Sitemap
Home
Find us on Facebook